Bepirovirsen Functional Cure Holds in 91% of Responders Through Week 96 in Chronic Hepatitis B
End-of-study B-Well trial data show 91% of hepatitis B patients who achieved functional cure with bepirovirsen kept it through Week 96, 48 weeks after stopping all HBV treatment.
Health & Medicine